mRNA-DC Vaccines
Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs), capable of processing and presenting antigens via major histocompatibility complex (MHC) class I and II molecules to both the innate and adaptive immune systems. DCs play a central role in initiating and regulating immune responses. Consequently, they have been extensively investigated as a means to stimulate cancer-specific T-cell responses.
mRNA is an attractive vector for delivering tumor antigens to dendritic cells (DCs). DCs can internalize mRNA CD8+ -encoded antigens via electroporation, introducing the mRNA into the cytoplasm, where it is translated into protein. The protein is then processed into peptides and presented on the cell surface to T cells.
Survivin-Targeting Dendritic Cell (DC) Cell Injection
- The first mRNA-DC Cancer Therapeutic Vaccine to Receive IND Approval in 2023
- This technology has advanced to Phase II clinical trials — the first of its kind in China — benchmarking against global frontrunners, with breakthrough outcomes in both long-term survival and safety.
- Safety Profile: The vaccine is safe and well-tolerated, with no DLT , no CRS, and no ICANS observed.
- Efficacy Data: At the low-dose level, mPFS exceeds 13 months to date, significantly outperforming the 6.9-month mPFS reported for the STUPP regimen.
CDE IND Approval
- Global first: 5-year continuous treatment induced a potent and durable tumor-specific T-cell immune response in the patient, with GBM patient survival >7 years.
· Wang QT, Nie Y, Sun SN, et al. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer
Immunol Immunother. 2020 Jul;69(7):1375-1387.
· Zhu P, Li SY, Ding J, et al. Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C. J
Pharm Anal. 2023 Jun;13(6):616-624.